Why You Don’t Need to Travel Overseas for Stem Cells

Almost every week a patient comes to Pravida Health asking the same question in slightly different words: Should I go to Panama? My neighbor went to a clinic in the Cayman Islands and says his knee is much better. It is a reasonable question. The marketing from overseas regenerative medicine clinics is sophisticated, the testimonials are compelling, and the procedures they are describing — culture-expanded mesenchymal stem cells (MSCs) — do have a real and growing evidence base. The problem is not the biology. The problem is everything else: the regulatory vacuum, the unverifiable product quality, the absence of follow-up, and the willingness of commercial overseas clinics to conflate research-grade outcomes data with what they are actually delivering.

This article is an attempt to answer the stem cell question honestly. What does the culture-expanded MSC evidence actually show? What is legally available to US patients who want access to these therapies? And why does traveling to Panama or the Cayman Islands not give you access to something better than what the US system offers — it gives you access to something materially worse, dressed in the language of cutting-edge medicine.

The Medical Tourism Problem

A cluster of destinations — Panama, the Cayman Islands, Colombia, Mexico — have built a substantial commercial infrastructure around marketing culture-expanded MSCs to US patients who cannot access these therapies domestically through standard clinical channels. The pitch is consistent: US regulators are holding back life-changing treatments; come to us and get the real thing.

The FDA has issued formal consumer warnings about unregulated stem cell clinics following documented adverse events. The case reports in the medical literature and in FDA safety communications include tumor formation at the injection site, systemic infections from contaminated cell preparations, embolic events, and in ophthalmologic cases, permanent vision loss. These are not theoretical risks from a regulator being cautious. They are outcomes that occurred in actual patients.

The structural problems with overseas commercial stem cell clinics are not correctable by choosing a “reputable” one:

• No FDA-mandated current Good Manufacturing Practice (cGMP) inspection of their labs — cell count, viability, sterility, and identity testing are self-reported, not independently verified
• No enforced chain-of-custody from tissue collection to injection
• No adverse-event reporting requirement — outcomes data from these clinics does not exist in any traceable registry
• No US IRB oversight of their protocols
• No continuity of care once you fly home — the treating physician in Atlanta who has to manage a complication from a Panama procedure has no records, no product information, and no recourse
• No malpractice recourse in the US legal system

The absence of adverse-event reporting is particularly significant. When a US clinical trial reports that a treatment had “no serious adverse events at four-year follow-up,” that is a meaningful statement because AEs were systematically collected and independently adjudicated. When an overseas clinic says the same thing, it means only that no patient filed a formal complaint with that clinic. The denominator is invisible.

Two Very Different Products Under One “Stem Cell” Label

Much of the confusion in this conversation stems from a single terminological problem: “stem cell therapy” is used to describe procedures that are biologically and legally quite different from each other. Understanding the distinction is essential to evaluating any claim — from an overseas clinic or a US physician.

The distinction that overseas clinics routinely blur is this: culture-expanded is not the same as same-day. A clinic in Panama offering “stem cells” for $15,000–$30,000 is offering a culture-expanded product manufactured in a facility that has never been inspected by the FDA or any equivalent authority with enforcement power. A US physician offering BMAC under Section 361 is offering a same-day autologous procedure under a defined regulatory framework. Neither is being dishonest about what they provide, in the narrow sense — but only one of them is operating in a system designed to catch problems before patients are harmed.

The reason cGMP matters goes beyond bureaucratic compliance. Culture-expanded MSCs must pass sterility testing (no contaminating organisms), identity testing (the cells are what the manufacturer claims), potency testing (the cells are biologically active), and viability testing (enough cells are alive to have a therapeutic effect) before release. These are not arbitrary hurdles. They are the difference between a therapeutic product and a vial of something that may or may not do what the label claims.

What the Culture-Expanded MSC Evidence Actually Shows

The evidence base for culture-expanded MSCs in osteoarthritis has matured considerably in the past five years, and it is more encouraging than it was — with important caveats about what the data actually demonstrates and what questions remain open.

The most comprehensive synthesis is the 2023 systematic review published in Cell & Molecular Immunology / Nature (PubMed 37095295), which analyzed 15 RCTs and 11 non-randomized studies of culture-expanded MSCs in knee osteoarthritis. The findings:

• 12 of 15 RCTs showed functional improvement vs baseline
• 11 of 15 RCTs showed functional improvement vs an active control group
• 18 of 21 imaging studies showed a cartilage protection or repair signal on MRI
• No serious adverse events were reported across trials, with follow-up extending to four years in some arms

This is a meaningful signal. It is not proof of efficacy by the standards required for FDA approval — the trials are heterogeneous in dose, cell source, and comparator — but it represents a consistent biological effect across a substantial body of controlled research.

The BJSM 2021 systematic review analyzed 14 RCTs with 408 patients and found that 73% of clinical outcome measures improved versus control at one year, with no serious adverse events at four-year maximum follow-up. At the individual study level, the Freitag 2019 RCT (PMID 30762487) enrolled 30 patients with autologous adipose-derived MSC (ADMSC) single or dual injection versus conservative management and found a disease-modifying MRI signal at 12 months — not just symptom relief, but structural evidence of cartilage response.

A 2025 network meta-analysis in Cureus (PMC12094297) compared autologous and allogeneic ADMSCs across eight RCTs and found that high-dose autologous MSCs performed best for pain at three, six, and twelve months (VAS SUCRA 82.27%), while high-dose allogeneic MSCs outperformed for long-term functional outcomes. This suggests that the optimal strategy may vary by patient goal and timeline, and that dose matters as much as cell source.

The longest follow-up data comes from a Korean study of autologous ADMSC (single high-dose injection, 1×10⁸ cells) that showed MRI structural improvement persisting to three years and clinical improvement persisting to five years — a meaningful durability signal for a field sometimes criticized for short follow-up periods (Stem Cells Translational Medicine, 2022).

The important caveat is this: every piece of evidence cited above comes from regulated research settings — US, European, or Korean IRB-approved trials with defined protocols, cGMP-manufactured cell products, and systematic outcome tracking. None of it is evidence for what a Panama or Cayman Islands commercial clinic is delivering. The research outcomes are not transferable to unregulated commercial settings.

What Is Legally Available in the United States

US patients who want access to culture-expanded MSCs have three legal pathways. None of them require traveling to a country with weaker regulatory oversight, and all of them come with protections that overseas clinics cannot offer.

1. FDA-Authorized IND Clinical Trials. Patients can enroll in an FDA-authorized investigational new drug (IND) trial at a US academic or research center. These trials use cGMP-manufactured cell products, have been reviewed by an independent IRB, and systematically collect safety and efficacy data. The Mayo Clinic has run NCT02805855, an autologous culture-expanded MSC trial for knee osteoarthritis, as one example of a US IRB-approved study. Current active trials can be searched at ClinicalTrials.gov.

2. Right to Try Act (2018). For patients with life-threatening or seriously debilitating conditions who have exhausted approved treatments and cannot participate in a clinical trial, the Right to Try Act provides a pathway to access an investigational biologic that has completed Phase I safety testing. The treating physician and the manufacturer must both agree, and the FDA must receive notification. This pathway has real constraints, but it is a lawful domestic route to pre-approval biologics.

3. Expanded Access (Compassionate Use). This is a physician-initiated FDA pathway for individual patients to access an investigational or unapproved biologic outside of a clinical trial. The treating physician submits an Expanded Access request to the FDA, which reviews it on an expedited basis for serious conditions. Like Right to Try, it requires a manufacturer willing to provide the product and a physician willing to oversee the treatment and submit required safety reports.

All three domestic pathways share characteristics that overseas commercial clinics cannot provide: a cGMP-manufactured product, US physician oversight, adverse-event reporting requirements, and continuity of care. They also share the same evidence base — the trials showing MSC efficacy in knee OA are the foundation for these pathways, not marketing for overseas alternatives.

What Overseas Clinics Do Not Have

It is worth being explicit about what patients give up when they choose an overseas commercial clinic, because the marketing from those clinics rarely mentions these gaps:

• No FDA-mandated cGMP inspection of their manufacturing facility — there is no independent verification of their sterility, identity, potency, or viability testing
• No enforced chain-of-custody from tissue source to the vial injected into your joint
• No standardized outcome tracking — there is no registry of outcomes at commercial overseas clinics, so the adverse-event rate is genuinely unknown
• No US IRB oversight of their protocols; informed consent is provided by the same entity that profits from the procedure
• No adverse-event registry — patients who have complications after returning to the US typically enter the domestic healthcare system with no documentation of what product was used, at what dose, from what lot
• No follow-up care once you fly home — the clinic that performed the procedure has no obligation or practical ability to monitor your outcome
• No malpractice recourse in the US legal system if something goes wrong

A patient who develops an infection or an embolic event after a Panama procedure is not the Panama clinic’s problem once they land at Hartsfield-Jackson. They are the Atlanta ER’s problem, and then their internist’s problem, and then their orthopedist’s problem — none of whom have any information about what was injected or how it was manufactured.

What Pravida Health Offers

At Pravida Health in Atlanta, we practice regenerative medicine within the legal and evidence-based framework — and we are direct about what that means in practice.

For most patients considering regenerative treatment for a joint, the appropriate starting point is a same-day autologous procedure under Section 361: bone marrow aspirate concentrate (BMAC), microfragmented adipose tissue (MFAT), or platelet-rich plasma (PRP). These procedures concentrate your own cells and growth factors at the point of care, require no FDA pre-authorization under 21 CFR Part 1271, and have their own evidence base for appropriate candidates. The BMAC vs MFAT comparative literature can help guide which approach is most appropriate for a given joint and degree of degeneration.

All procedures at Pravida are performed under ultrasound or fluoroscopic guidance by Dr. Turner, a board-certified physician (MD, DABPMR) who conducts the diagnostic evaluation, performs the procedure, and provides follow-up care. We do not use blind injection techniques. Real informed consent means explaining what the evidence supports for the specific joint being treated, not overpromising outcomes that the literature does not back.

For patients who are specifically seeking culture-expanded MSCs after reviewing the evidence: we help them navigate US IRB-approved clinical trials and, where appropriate, can work with their treating physicians to explore Right to Try or Expanded Access pathways. We do not refer patients to overseas clinics. The domestic pathways provide the same biological product with materially better safety infrastructure.

Frequently Asked Questions

References

1. Yubo M, Yanyan L, Li L, et al. Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis. Cell Mol Immunol. 2023. Available at: PubMed 37095295
2. Yubo M et al. Nature Cell & Molecular Immunology 2023 systematic review of culture-expanded MSCs in knee OA. Available at: Nature Cell Mol Immunol 2023
3. Pas H, Winters M, Haisma HJ, et al. Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med. 2021;55(20):1161–1169. Available at: BJSM 2021 systematic review
4. Freitag J, Bates D, Wickham J, et al. Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis. Regen Med. 2019. Available at: Freitag 2019 RCT (PMID 30762487)
5. Abutaleb N, et al. Network meta-analysis of autologous vs allogeneic adipose-derived MSCs in knee OA. Cureus. 2025. Available at: Cureus 2025 NMA (PMC12094297)
6. Song Y, Du H, Dai C, et al. Autologous adipose-derived stromal vascular fraction for knee osteoarthritis: 5-year follow-up. Stem Cells Transl Med. 2022;11(6):586–597. Available at: 5-year Korean ADMSC study
7. ClinicalTrials.gov. NCT02805855 — Mayo Clinic autologous culture-expanded MSC, knee OA. Available at: NCT02805855 Mayo trial
8. Vega A, et al. Treatment of knee osteoarthritis with allogeneic bone marrow MSCs: randomized controlled pilot study. Stem Cells Transl Med. 2019;8(11):1149. Available at: BMAC vs MFAT comparison study
9. U.S. Food & Drug Administration. Right to Try. Available at: FDA Right to Try
10. Electronic Code of Federal Regulations. 21 CFR Part 1271 — Human cells, tissues, and cellular and tissue-based products. Available at: FDA 21 CFR 1271
11. U.S. Food & Drug Administration. FDA warns about stem cell therapies. Available at: FDA warning on unapproved stem cell clinics